Aarti Financial Statements From 2010 to 2025

Stocks . India . 
Stock . Aarti Drugs Limited
AARTIDRUGS   357.90  10.25  2.95%   
Aarti Drugs financial statements provide useful quarterly and yearly information to potential Aarti Drugs Limited investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aarti Drugs financial statements helps investors assess Aarti Drugs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aarti Drugs' valuation are summarized below:
Gross Profit
8.1 B
Profit Margin
0.0655
Market Capitalization
32.7 B
Enterprise Value Revenue
1.6167
Revenue
23.3 B
There are over eighty-six available fundamental signals for Aarti Drugs Limited, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Aarti Drugs' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction.

Aarti Drugs Total Revenue

30.29 Billion

Check Aarti Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aarti Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 367.1 M, Interest Expense of 315 M or Selling General Administrative of 171.3 M, as well as many indicators such as . Aarti financial statements analysis is a perfect complement when working with Aarti Drugs Valuation or Volatility modules.
  
This module can also supplement various Aarti Drugs Technical models . Check out the analysis of Aarti Drugs Correlation against competitors.

Aarti Drugs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.4 B28 B15.5 B
Slightly volatile
Short and Long Term Debt Total4.3 B6.5 B4.5 B
Slightly volatile
Total Current Liabilities5 B9.1 B5.8 B
Slightly volatile
Total Stockholder Equity15.5 B14.7 B6.8 B
Slightly volatile
Property Plant And Equipment Net12.7 B12.1 B6.6 B
Slightly volatile
Net Debt4.2 B6.4 B4.4 B
Slightly volatile
Cash65.7 M77.5 M62.8 M
Slightly volatile
Non Current Assets Total13.4 B12.8 B6.9 B
Slightly volatile
Cash And Short Term Investments74.5 M102.7 M73.9 M
Slightly volatile
Net Receivables4.1 B8.1 B4.6 B
Slightly volatile
Common Stock Shares Outstanding75.8 M82.7 M92.8 M
Slightly volatile
Liabilities And Stockholders Equity29.4 B28 B15.5 B
Slightly volatile
Non Current Liabilities Total2.6 B4.1 B2.5 B
Slightly volatile
Inventory5.9 B5.6 B3.1 B
Slightly volatile
Other Current Assets863.3 M1.4 B916 M
Pretty Stable
Total Liabilities7.6 B13.2 B8.3 B
Slightly volatile
Total Current Assets15.9 B15.2 B8.6 B
Slightly volatile
Common Stock1.1 B1.1 B486.2 M
Slightly volatile
Accounts Payable2.8 B5.2 B2.7 B
Slightly volatile
Retained Earnings13.9 B13.3 B5.9 B
Slightly volatile
Short Term Debt3.1 B3.3 B2.9 B
Slightly volatile
Intangible Assets444.7 M423.5 M115 M
Slightly volatile
Short Term Investments23.9 M25.1 M69.1 M
Pretty Stable
Other Liabilities949 M1 B800.1 M
Slightly volatile
Net Tangible Assets14.4 B13.7 B6.8 B
Slightly volatile
Long Term Debt2 B3.2 B1.7 B
Slightly volatile
Long Term Investments89.9 M143 M92.7 M
Slightly volatile
Short and Long Term Debt2.8 B3.3 B2.8 B
Very volatile
Property Plant Equipment6.8 B10.2 B6.2 B
Slightly volatile
Long Term Debt Total1.5 B1.8 B1.9 B
Slightly volatile
Net Invested Capital15 B21.2 B12.6 B
Slightly volatile
Net Working Capital4.1 B6 B2.7 B
Slightly volatile
Capital Stock764.9 M1.1 B492.6 M
Slightly volatile
Capital Lease Obligations15.9 M16.7 M69.6 M
Slightly volatile
Property Plant And Equipment Gross8.5 B9.3 B10.3 B
Slightly volatile

Aarti Drugs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization367.1 M591.6 M390.4 M
Slightly volatile
Interest Expense315 M435.7 M321.2 M
Slightly volatile
Selling General Administrative171.3 M163.1 M83.2 M
Slightly volatile
Selling And Marketing Expenses353.7 M663.4 M391.1 M
Slightly volatile
Total Revenue30.3 B28.9 B16.6 B
Slightly volatile
Gross Profit3.1 B4 B3.4 B
Slightly volatile
Other Operating Expenses27.2 B25.9 B14.6 B
Slightly volatile
Operating Income3.4 B3.2 B1.8 B
Slightly volatile
EBIT1.7 B3.1 B1.9 B
Slightly volatile
EBITDA2 B3.7 B2.3 B
Slightly volatile
Cost Of Revenue26.1 B24.8 B13.2 B
Slightly volatile
Total Operating Expenses1.4 B1.3 B1.5 B
Slightly volatile
Income Before Tax2.8 B2.7 B1.6 B
Slightly volatile
Net Income2.1 B2 B1.2 B
Slightly volatile
Income Tax Expense772 M735.3 M434.6 M
Slightly volatile
Research Development67.4 M96 M61.5 M
Slightly volatile
Net Income From Continuing Ops1.4 B2 B1.2 B
Slightly volatile
Net Income Applicable To Common Shares1.4 B1.9 B1.2 B
Slightly volatile
Tax Provision566.4 M735.3 M454 M
Slightly volatile
Interest Income21.3 M22.5 M294.5 M
Slightly volatile
Reconciled Depreciation523.4 M591.7 M453.1 M
Slightly volatile

Aarti Drugs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow66.3 M86.3 M64.1 M
Slightly volatile
Depreciation367.1 M591.6 M390.4 M
Slightly volatile
Dividends Paid104.7 M106.6 M105.2 M
Very volatile
Capital Expenditures2.7 B2.6 B1.2 B
Slightly volatile
Total Cash From Operating Activities4.3 B4.1 B1.7 B
Slightly volatile
Net Income1.3 B2 B1.4 B
Slightly volatile
End Period Cash Flow68.2 M77.5 M65.5 M
Slightly volatile
Change To Netincome284.1 M297.2 M334.6 M
Pretty Stable

Aarti Fundamental Market Drivers

Cash And Short Term Investments89.3 M

About Aarti Drugs Financial Statements

Aarti Drugs shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aarti Drugs investors may analyze each financial statement separately, they are all interrelated. The changes in Aarti Drugs' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aarti Drugs' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue13.6 M12.9 M
Total Revenue28.9 B30.3 B
Cost Of Revenue24.8 B26.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
SSentinelOne
GMGeneral Motors

Additional Tools for Aarti Stock Analysis

When running Aarti Drugs' price analysis, check to measure Aarti Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarti Drugs is operating at the current time. Most of Aarti Drugs' value examination focuses on studying past and present price action to predict the probability of Aarti Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarti Drugs' price. Additionally, you may evaluate how the addition of Aarti Drugs to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY